The How And Why Behind Mirimus Getting Into The Business Of COVID-19 Testing
Source: Life Science Leader
In this executive virtual roundtable (EVR) section, Prem Premsrirut, M.D., Ph.D., CEO, Mirimus, an RNAi therapeutics company, shares the how and why behind the decision to develop a saliva-based test for COVID-19.
This website uses cookies to ensure you get the best experience on our website. Learn more